Blog
RSS FeedPosted by Michael Wonder on 05 Feb 2022
TGA approves provisional determination for Gilead for COVID-19 treatment, Veklury (remdesivir), for proposed use in children and adults who are at risk of progressing to severe COVID-19
5 February 2022 - The TGA has granted a second provisional determination to Gilead in relation to its COVID-19 treatment, ...
Posted by Michael Wonder on 03 Feb 2022
COVID-19 vaccine weekly safety report (3 February 2022)
3 January 2022 - To 30 January 2022, the TGA has received 440 reports which have been assessed as likely ...
Posted by Michael Wonder on 02 Feb 2022
ATAGI recommendations for use of Pfizer COVID-19 vaccine as a booster dose in adolescents aged 16-17 years
3 January 2022 - The Australian Technical Advisory Group on Immunisation (ATAGI) has made recommendations for use of Pfizer COVID-19 vaccine ...
Posted by Michael Wonder on 28 Jan 2022
Pfizer's COVID-19 vaccine (Comirnaty) provisionally approved for use as a booster in individuals aged 16-17 years old
28 January 2022 - The Therapeutic Goods Administration has provisionally approved the Pfizer COVID-19 vaccine, Comirnaty for use as a ...
Posted by Michael Wonder on 27 Jan 2022
Moderna aims to deliver Omicron COVID-19 vaccine by September
27 January 2022 - A COVID-19 booster shot, targeted specifically at the Omicron variant, is expected to be delivered by ...
Posted by Michael Wonder on 27 Jan 2022
COVID-19 vaccine weekly safety report (27 January 2022)
27 January 2022 - To 23 January 2022, the TGA has received 431 reports which have been assessed as likely to ...
Posted by Michael Wonder on 23 Jan 2022
ATAGI statement on the use of Novavax COVID-19 vaccine (Nuvaxovid)
24 January 2022 - ATAGI recommends that Novavax COVID-19 vaccine can be used for the primary course of COVID-19 vaccination ...
Posted by Michael Wonder on 20 Jan 2022
COVID-19 vaccine weekly safety report (20 January 2022)
20 January 2022 - To 16 January 2022, the TGA has received 428 reports which have been assessed as likely to ...
Posted by Michael Wonder on 20 Jan 2022
Statement on the arrival of the Novavax vaccine and COVID-19 pills
20 January 2022 - Medicines Australia welcomes the TGA’s provisional approval for the Novavax COVID-19 vaccine and the provisional approval ...
Posted by Michael Wonder on 20 Jan 2022
Two anti-viral COVID-19 treatments approved
20 January 2022 - The Australian Government welcomes the Therapeutic Goods Administration’s provisional approval of the first oral treatments for COVID-19 ...
Posted by Michael Wonder on 20 Jan 2022
TGA provisionally approves Novavax (Biocelect) COVID-19 vaccine Nuvaxovid
20 January 2022 - The Therapeutic Goods Administration has granted provisional approval to Biocelect (on behalf of Novavax) for its ...
Posted by Michael Wonder on 19 Jan 2022
TGA provisionally approves two oral COVID-19 treatments, molnupiravir (Lagevrio) and nirmatrelvir and ritonavir (Paxlovid)
20 January 2022 - The TGA has granted provisional approval to two oral COVID-19 treatments: Paxlovid (nirmatrelvir and ritonavir, Pfizer) ...
Posted by Michael Wonder on 19 Jan 2022
Lieutenant General John Frewen says he expects TGA approval of Novavax vaccine is 'imminent'
19 January 2022 - The head of Australia's vaccine rollout expects one to two per cent of Australians who remain unvaccinated ...
Posted by Michael Wonder on 17 Jan 2022
TGA recognises the Gamaleya Institute vaccine (Sputnik V, Russian Federation) for international travel to Australia
17 January 2022 - Today, the TGA determined that an additional COVID-19 vaccine, the two dose course of the Gamaleya ...
Posted by Michael Wonder on 17 Jan 2022
ATAGI update following weekly COVID-19 meeting (12 January 2022)
17 January 2022 - Previously, severely immunocompromised people aged 12 years and older were recommended to receive a third primary dose ...